Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib.

Gastroenterol Res Pract · 2014 · PMC3920623 · PMID 24587795

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significanceP = 0.058so close (0.05 < p ≤ 0.1)

The survival curves apparently separated at 18 months for median survival time (hazard ratio (HR) = 0.332; 95% confidence interval (CI), 0.103–1.070), but the differences between the two groups did not reach statistical significance in the log-rank test for overall survival ( P = 0.058).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.